NFKB1 and ischemic stroke: Consistent with this assumption, small molecules able to reduce NF-κB activation have been tested in rodent models of ischemic stroke producing desirable outcomes (e.g., suppressing production of inflammatory cytokines, reducing cerebral edema, infarct sizes, and neurological deficits) [10].